OCE Scientific Collaborative
OCE Scientific Collaborative
Related Articles
Eftilagimod Alpha Plus Pembrolizumab/Chemo Generates Improved Survival Trends in Advanced NSCLC
Eftilagimod alpha plus pembrolizumb and chemotherapy generated favorable survival data in nonsquamous NSCLC.
Perioperative Nivolumab Plus Chemotherapy Represents the Future of Personalized NSCLC Care
Mark Awad, MD, PhD, and Jonathan Spicer, MD, PhD, discuss the FDA approval of perioperative nivolumab for patients with resectable NSCLC.
Sylvester Annual Oncology Update Highlights Different Perspectives in Bladder Cancer, Other Treatment Areas
Janaki Neela Sharma, MD, discusses takeaways from the Sylvester Comprehensive Cancer Center 2024 Annual Oncology Update.
Personalized Initiatives Empower Patients to Actively Participate in Cancer Research
Investigators who champion patient-partnered cancer research have experienced challenges to their effective implementation.
Radiation-Associated Secondary Cancer in Patients With Breast Cancer
This cohort study examines the risk of radiation-associated sarcoma in patients with breast cancer harboring germline TP53 variants.
SCLC Staging Determines Treatment, Adverse Events
The staging of small cell lung cancer significantly impacts treatment plans and potential side effects.
Telehealth speeds access to clinical trials for cancer
Physicians @OSUCCC_James are pioneering telehealth to give more patients access to lifesaving clinical trials.
Low-Risk Individuals Should Not Currently Be Screened for… : Oncology Times
An abstract is unavailable.
NCCN Expands Genetic Risk Assessment Guidelines to Include Additional Tumor Types
National Comprehensive Cancer Network updated 2 guideline resources to keep providers and other stakeholders up to date on cutting-edge genetic research.
Laying the groundwork for a new cancer-preventive vaccine
Three Fred Hutch Cancer Center researchers received a five-year, $3.8 million award from the National Cancer Institute to delve into the “black box” of our…
